Multivariate optoacoustic sensor for longitudinal diabetes monitoring

Introduction

MOSAIC will radically miniaturize non-invasive optoacoustic technology and make it portable by coupling optoacoustic sensing to novel explainable artificial Intelligence (xAI) to monitor a major health threat in the 21st century: Diabetes Mellitus.

Technology Overview

MOSAIC is based on recent advances in optoelectronic miniaturization and uses the skin as a window to dermal microvasculature, resolving a large number of biomarkers associated with diabetes. The technology is offered as a fast sensor that is inexpensive and reliable, entirely non-invasive and portable, and supported by elaborate quality control monitoring so that it can be employed for long-term patient monitoring.

Predictive Power

Based on proof-of-concept human measurements, xAI will further independently characterize the predictive power of each biomarker and other clinical measurements to improve accuracy for continuous grading of disease status.

Impact

With 537 million diabetics and a large at-risk population, MOSAIC potentially relates to 2 billion people and aims to reach more individuals than is practical to screen in medical facilities. It offers early diabetes detection for early interventions, as well as treatment monitoring, improving life expectancy, quality of life, and reducing healthcare costs.

Innovation

The sensor addresses five barriers to successful adoption:

1. It is non-invasive.
2. It senses highly multiplexed biomarkers.
3. It can be easily integrated into daily routine.
4. It uses fully automated data analytics.

Team Collaboration

MOSAIC synergistically integrates three teams on sensor developments, data analytics, and xAI, one preclinical and one clinical team for sensor validation in mice and humans, respectively, and an SME for exploitation.